Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients

A technology of active ingredients and compositions, applied in the field of pharmaceutical compositions containing high-efficiency and long-acting β2-agonists and other active ingredients, can solve problems such as undetermined effective and safe doses
CN1753678AInactive Publication Date: 2006-03-29CHIESI FARM SPA
13 Cites 7 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
CHIESI FARM SPA
Publication Date
2006-03-29
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates to the use of a bronchodilator in combination with one or more further active ingredients for the treatment of respiratory disorders and especially asthma and chronic obstructive pulmonary disease (COPD), and to pharmaceutical compositions containing said active ingredients. In particular, the invention relates to the use of the long-acting beta2-agonist 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1methylethyl]amino]ethyl-2(1H)-quinolinone and / or physiologically acceptable salts and / or solvates thereof as a bronchodilator in combination with other active ingredients.
Need to check novelty before this filing date? Find Prior Art

Description

Background of the invention

[0001] Asthma is a disease that is becoming more common and is one of the most common childhood diseases. It can be identified by recurrent wheezing and intermittent airflow limitation. Despite many advances in its understanding, its pathology remains an underrecognized and often poorly treated disease.

[0002] Previously, contraction of airway smooth muscle was considered the most important feature of asthma. There have been significant changes in the management of asthma due to the recognition that asthma is a chronic inflammatory disease. Uncontrolled airway inflammation may lead to mucosal damage and structural changes, leading to irreversible narrowing of the airways and fibrosis of lung tissue. The goal of treatment should therefore be to control symptoms to enable normal life while providing a basis for treating the underlying inflammation.

[0003] Symptoms can be controlled by: First Generation Beta 2 - Adrenoceptor agonists such as a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More